Thomas Karalis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas karalis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Karalis Today - Breaking & Trending Today

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to. ....

United States , United Kingdom , Northern Ireland , Hong Kong , South Korea , Thomas Karalis , Asia Pacific , Peter Qian , Hong Kongchina , Jay Mei , Prnewswire Antengene Corporation Limited , Department Of Health , Karyopharm Therapeutics Inc , Antengene Corporation Limited , Company Named Patient Program , European Society Of Medical Oncology , Hong Kong Stock Exchange , European Union , International Myeloma Foundation , Company Annual , International Myeloma Working Group , National Cancer Care Network , Chinese Society Of Clinical Oncology , Antengene Corporation , Cancer Association Guidelines For The Holistic , Taiwan China ,

Antengene's multiple myeloma therapy approved in Hong Kong

Antengene has received approval in Hong Kong for a new drug application (NDA) for Xpovio (selinexor) to treat multiple myeloma (R/R MM). ....

United Kingdom , Hong Kong , Nemes Laszlo Shutterstock , Thomas Karalis , Antengene Asia Pacific , Department Of Health , European Union , Nemes Laszlo , Hong Kong Special Administrative Region , Asia Pacific Region ,

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Indonesia National Agency of Drug and Food. ....

South Korea , Hong Kong , Peter Qian , Jay Mei , Asia Pacific , Thomas Karalis , Hong Kong Stock Exchange , Indonesia National Agency Of Drug , Karyopharm Therapeutics Inc , Company Annual , Antengene Corporation Limited , New Drug Applications , Indonesia National Agency , Food Control , Corporate Vice President , Karyopharm Therapeutics , Corporation Limited , Patients Beyond , Taiwan China , Annual Report , Hong Kong Stock ,

Antengene Announces NDA Submission for XPOVIO in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In Q4 2022, Antengene also submitted NDAs for XPOVIO in Malaysia and Thailand. "In just six months, we have submitted NDAs for XPOVIO in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting our plans to expand commercial presence in the APAC region," said Thomas Karalis, Antengene's Corporate Vice President, Head of Asia Pacific Region. "In a region ....

South Korea , Hong Kong , Asia Pacific , Peter Qian , Jay Mei , Thomas Karalis , Antengene Corporation Limited , Hong Kong Stock Exchange , Karyopharm Therapeutics Inc , Company Annual , Indonesia National Agency Of Drug , New Drug Applications , Indonesia National Agency , Food Control , Corporate Vice President , Karyopharm Therapeutics , Corporation Limited , Patients Beyond , Taiwan China , Annual Report , Hong Kong Stock , Shanghai And Hong Kong , May 17 , 023 Prnewswire Antengene Corporation Limited Quot Sehk 6996 Hk , A Leading Innovative , Ommercial Stage Global Biopharmaceutical Company Dedicated To Discovering ,

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma ....

Hong Kong , South Korea , Thomas Karalis , Jay Mei , Asia Pacific , Peter Qian , Karyopharm Therapeutics Inc , Company Annual , Malaysian National Pharmaceutical Regulatory Agency , Hong Kong Stock Exchange , Antengene Corporation Limited , Administration Bureau Of Macau , Drug Authority , New Drug Applications , Pharmaceutical Administration Bureau , Thai Food , Corporate Vice President , Karyopharm Therapeutics , Corporation Limited , Patients Beyond , Greater China , Annual Report , Hong Kong Stock , Antengene Announces Nda Submission For Xpovio In Macau , Alaysia And Thailand For Relapsed Refractory Multiple Myeloma Diffuse Largeb Cell Lymphoma ,